Company Encyclopedia
View More
name
Bioline RX
BLRX.US
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd.
1.946 T
BLRX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking314/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-21.24%E
    • Profit Margin-23.38%E
    • Gross Margin80.33%A
  • Growth ScoreD
    • Revenue YoY-42.09%E
    • Net Profit YoY85.05%A
    • Total Assets YoY-24.53%E
    • Net Assets YoY129.66%A
  • Cash ScoreE
    • Cash Flow Margin-427.78%E
    • OCF YoY-42.09%E
  • Operating ScoreD
    • Turnover0.28D
  • Debt ScoreC
    • Gearing Ratio50.93%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges

    BioLineRx's Q3 earnings call highlighted strategic initiatives amid revenue challenges. The company is focusing on innovative treatments and has a strong cash position, despite minimal revenue growth. A joint venture with Hemispherian aims to develop GLIX1 for cancer treatment, with FDA clearance for trials in 2026. BioLineRx reported reduced net loss and expenses, with a solid cash position to sustain operations until 2027. The company remains optimistic about future prospects in cancer treatment, despite slow market penetration.

    Tip Ranks·
    US
    BLRX
    +1.15%
    Tip Ranks·
    US
    BLRX
    +1.15%

    BioLineRx reports $0.4 million in third quarter 2025 revenues

    BioLineRX Ltd. reported $0.4 million in revenues for Q3 2025, primarily from royalties related to APHEXDA's commercialization in the U.S. This is a decrease from Q3 2024, which included significant upfront payments and sales. The company also reported a net financial income of $0.1 million, a shift from a $1.2 million expense in 2024, due to loan paydowns. Additionally, BioLineRX formed a joint venture with Hemispherian AS to advance GLIX1, with clinical trials expected in early 2026.

    Reuters·
    US
    BLRX
    +1.15%
    Reuters·
    US
    BLRX
    +1.15%

    Options Volatility and Implied Earnings Moves Today, November 24, 2025

    Several major companies are reporting earnings today, including Agilent, Bioline RX, and Zoom Video Communications. TipRanks offers insights into expected earnings moves based on options prices, helping investors anticipate stock movements post-announcement. Companies reporting before market open include BLRX and LX, while those reporting after market close include A, PFLT, and ZM. Implied earnings moves vary, with BLRX at +/- 187.69% and ZM at +/- 8.20%. Investors are advised to conduct thorough research due to the risks of options trading.

    Tip Ranks·
    US
    ZM
    +1.10%
    US
    BLRX
    +1.15%
    Tip Ranks·
    US
    ZM
    +1.10%
    US
    BLRX
    +1.15%

    07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    BioLineRx Ltd. reported its Q3 2025 financial results and announced a joint venture with Hemispherian AS to advance GLIX1, targeting glioblastoma. A Phase 1/2a trial is set for Q1 2026. The company maintains a cash runway into H1 2027. Additionally, BioLineRx received a Notice of Allowance for a key patent on GLIX1, extending protection until 2040. The CheMo4METPANC trial for motixafortide in pancreatic cancer continues, and results from a Phase 1 trial for sickle cell disease will be presented at the ASH Annual Meeting.

    prnewswire·
    US
    BLRX
    +1.15%
    prnewswire·
    US
    BLRX
    +1.15%

    BioLineRx Forms Joint Venture With Hemispherian to Advance Cancer Therapy

    BioLineRx Ltd. has formed a joint venture with Hemispherian AS to develop GLIX1, an oral small molecule targeting DNA damage response in glioblastoma and other cancers. A Phase 1/2a clinical trial is set to begin in Q1 2026. This collaboration expands BioLineRx's cancer treatment pipeline.

    Reuters·
    US
    BLRX
    +1.15%
    Reuters·
    US
    BLRX
    +1.15%
    © 2025 Longbridge｜Disclaimer